Related by context. All words. (Click for frequent words.) 72 oral proteasome inhibitor 72 alpha folate receptor 69 PNP inhibitor 68 proteasome inhibitor 66 multi kinase inhibitor 66 PDE4 inhibitor 65 selective kinase inhibitor 65 liposomal formulation 65 ALN TTR 65 AEG# 65 AQ4N 64 metaglidasen 64 targeted radiotherapeutic 64 orally administered inhibitor 64 tumor vascular disrupting 64 PSMA ADC 64 histone deacetylase HDAC inhibitor 64 Panzem R NCD 64 mertansine 64 MEK inhibitor 64 Targeted Chemotherapy 64 XL# anticancer compounds 64 small molecule Hedgehog 64 HCD# [002] 63 Amrubicin 63 TKB# 63 Ceflatonin R 63 Traficet EN 63 drug conjugate 63 XmAb# 63 HGS# 63 MAGE A3 ASCI 63 Tamibarotene 63 Voreloxin 63 Vicinium TM 63 CYT# potent vascular disrupting 63 forodesine 63 IAP inhibitor 63 targeted antifolate 63 Nanobody 63 radiation sensitizer 63 non nucleoside inhibitor 63 mTOR inhibitor 63 PF # [001] 63 JAK inhibitor 62 Allovectin 7 62 candidate CRLX# 62 relapsed multiple myeloma 62 Pralatrexate 62 CTAP# Capsules 62 carfilzomib 62 JAK1 62 XL# XL# 62 Onco TCS 62 vinorelbine tartrate 62 R#/MEM 62 Nexavar ® 62 CCX# 62 Blinatumomab 62 antibody MAb 62 HCV protease inhibitor 62 somatostatin analogue 62 dasatinib Sprycel ® 62 investigational humanized monoclonal antibody 62 generation purine nucleoside 62 oral prodrug 62 MT# MEDI 62 angiogenesis inhibitor 62 Archexin 62 estrogen receptor antagonist 62 tiapamil 62 refractory chronic lymphocytic 62 ALN HPN 62 volociximab 62 Lenalidomide 62 HuMax CD4 62 Hsp# Inhibitor 62 Daclizumab 61 Ecallantide 61 Aflibercept 61 investigational immunotherapy 61 Perifosine 61 Xanafide 61 mGluR5 negative 61 TREANDA 61 Irinotecan 61 developing Bicifadine serotonin 61 selective androgen receptor modulator 61 depsipeptide 61 Annamycin 61 Omacetaxine 61 opioid induced bowel dysfunction 61 XL# XL# XL# 61 IgG1 antibody 61 dacetuzumab 61 oral ridaforolimus 61 CBLC# 61 non nucleoside 61 OncoVEX GM CSF 61 Azedra 61 mGluR2 positive 61 phase IIb clinical 61 IAP inhibitors 61 INCB# [001] 61 MGd 61 leading oral taxane 61 Bezielle 61 TELINTRA 61 AKT inhibitor 61 BAY #-# 61 CYC# 61 relapsing multiple sclerosis 61 Debio 61 investigational monoclonal antibody 61 romazarit 61 Xeloda ® 61 huC# DM4 61 TRC# 61 immunotherapeutic agent 61 AVONEX ® 61 selective agonist 60 Dapagliflozin 60 Phase IIa trials 60 BrachySil TM 60 evaluating tivozanib 60 seliciclib CYC# 60 Xyfid TM 60 orally dosed 60 Troxatyl 60 AzaSite Plus 60 PrevOnco ™ 60 PN# [001] 60 Phase #b/#a clinical 60 SAR# [004] 60 lintuzumab SGN 60 Neulasta ® 60 HGS ETR1 60 HIV integrase inhibitor 60 ADP receptor antagonist 60 cathepsin K inhibitor 60 Alocrest 60 reslizumab 60 Phase Ib II 60 anticancer compound 60 MEK inhibitors 60 OXi# 60 Vandetanib 60 ARRY # 60 IMC #B 60 LHRH antagonist 60 PrevOnco 60 Trastuzumab 60 Bicifadine 60 small molecule tyrosine 60 Testim R 60 Panzem R 60 AEGR 60 Pertuzumab 60 orally inhaled 60 cutaneous T 60 Albuferon TM 60 sodium glucose cotransporter 60 CCR2 60 tumors GIST 60 ulimorelin 60 Taiho Pharmaceutical 60 EOquin TM 60 pan HDAC inhibitor 60 JAK inhibitors 60 protein kinase inhibitor 60 humanized monoclonal antibody 60 OMNARIS Nasal Spray 60 5 HT3 antagonist 60 Bortezomib 60 signal transduction inhibitor 60 Mipomersen 60 Ixempra 60 PRX# 60 telomerase inhibitor drug 60 orally bioavailable 60 subcutaneous formulation 60 Guanilib 60 relapsed refractory multiple myeloma 60 targeting CD# 60 LymphoStat B TM 60 PLK1 SNALP 60 HuMax 60 PEG SN# 60 EGFR HER2 60 peripherally acting 60 HuMax EGFr 60 cetuximab Erbitux R 60 CD# CEA 60 HuLuc# 60 ATL# [001] 60 thalidomide Thalomid 60 refractory multiple myeloma 60 HQK 60 triciribine phosphate monohydrate 60 bendamustine 59 MKC# MKC# PP 59 vidofludimus 59 Insegia 59 paclitaxel Taxol ® 59 including eniluracil ADH 59 CEQ# 59 erlotinib Tarceva ® 59 Zensana TM 59 tyrosine kinase inhibitor TKI 59 MNTX 59 Elotuzumab 59 renin inhibitor 59 ChronVac C R 59 Tarceva TM 59 Sym# 59 Prestara 59 R sorafenib tablets 59 alvespimycin 59 ENMD # 59 Aurora kinase 59 IMC A# 59 CCX# B 59 APOPTONE 59 Phase Ib study 59 TOCOSOL Paclitaxel 59 anticancer agent 59 Levoleucovorin 59 Forodesine 59 NeoLipid R 59 PEGylated interferon 59 RAV# 59 docetaxel Taxotere R 59 INT# [002] 59 FOLOTYN ® 59 Dasatinib 59 humanized antibody 59 TRX1 59 PLX# 59 Aplidin R 59 PARP inhibitor 59 recurrent NSCLC 59 topical gel formulation 59 immunomodulatory therapy 59 Tesetaxel 59 VEGFR2 inhibitor 59 Hedgehog pathway inhibitor 59 polymerase inhibitor 59 proteasome inhibitor bortezomib 59 Factor VIIa 59 Vaprisol 59 vapreotide acetate 59 prokinetic agent 59 Ofatumumab 59 farletuzumab 59 Amigal 59 Kissei Pharmaceutical 59 XP# XP# 59 PEGylated Fab fragment 59 histone deacetylase inhibitor 59 Copegus ribavirin 59 inhaled formulation 59 RNAi therapeutic targeting 59 ENMD 59 visilizumab 59 proprietary polysaccharide 59 Oral NKTR 59 LEUKINE 59 PF # [002] 59 IMA# 59 JAK2 inhibitor 59 bevacizumab Avastin ® 59 pertuzumab 59 RGB # 59 vascular disrupting agent 59 CD# monoclonal antibody 59 NXL# 59 XL# XL# XL# XL# 59 gefitinib Iressa 59 Liposomal 59 novel anticancer 59 intranasal formulation 59 Sapacitabine 58 CytoFabTM 58 PDX pralatrexate 58 immunomodulator 58 sunitinib malate 58 huN# DM1 58 phase IIa clinical 58 Virulizin ® 58 RhuDex ® 58 HCV polymerase inhibitor 58 virus HCV protease inhibitor 58 alkylating agent 58 selective A2A adenosine receptor 58 Seliciclib 58 R#/MEM # 58 Cloretazine ® 58 Investigational Oral 58 PEG IFN 58 Degarelix 58 PKC# 58 Ceflatonin 58 ribavirin Copegus ® 58 Azixa 58 epothilone 58 LEP ETU 58 CTCE 58 Tyrosine Kinase Inhibitor 58 HGS ETR2 58 cMet 58 CCR5 antagonist 58 YONDELIS 58 gemcitabine cisplatin 58 Glufosfamide 58 ORENCIA R 58 entinostat 58 LY# [003] 58 Temsirolimus 58 RH1 58 fallopian tube cancers 58 sodium thiosulfate STS 58 adenosine injection 58 NanoTab 58 mitogen activated ERK kinase 58 EOquin 58 MAXY G# 58 AERx R 58 OvaRex ® MAb 58 novel emulsion formulation 58 HDAC Inhibitor 58 ® bortezomib 58 VELCADE melphalan 58 novel histone deacetylase 58 ThermoDox R 58 histamine dihydrochloride 58 Phase IIb clinical trials 58 oncolytic vaccine 58 metastatic CRC 58 Soliris eculizumab 58 PARI Pharma GmbH 58 CORT # 58 deforolimus 58 celgosivir 58 Nimotuzumab 58 Aloxi injection 58 Allovectin 7 R 58 IIIa inhibitor 58 ARC# [001] 58 Xcellerated T Cells 58 Cetuximab Erbitux 58 Amplimexon 58 metastatic neuroendocrine tumors 58 Tavocept 58 atacicept 58 oral antiviral 58 p# inhibitor 58 systemically administered 58 UVIDEM 58 GRN# 58 elotuzumab 58 GED aPC 58 Tarvacin 58 ganetespib 58 cell lymphoma CTCL 58 MuGard TM 58 cilengitide 58 Phase Ib clinical trials 58 Erlotinib 58 Onconase 58 ONTAK 58 GRN#L 58 GV# [001] 58 Alfimeprase 58 mRNA antagonists 58 Orally administered 58 IRX 2 58 BENLYSTA ® 58 Inhalation Solution 58 docetaxel Taxotere ® 58 TG# [003] 58 PI3K/Akt pathway inhibitor 58 Chemophase 58 eniluracil 58 Solzira TM 58 Medoxomil 58 rhIL 7 58 ZACTIMA 58 Chemokine Receptor 58 imatinib Gleevec ® 58 Gleevec resistant 58 humanized anti 58 VISICOL R 58 Celgosivir 58 Phase 2a Clinical Trial 58 investigational HCV polymerase 58 Gemzar ® 58 FLT3 58 VQD 58 metastatic colorectal 58 receptor tyrosine kinase inhibitor 58 TYKERB 58 Panitumumab 58 tyrosine kinase inhibitor 58 perifosine KRX 58 Belinostat 58 oncology indications 58 WP# [002] 58 R roscovitine 58 Cleviprex TM clevidipine 58 leukemia AML 58 lintuzumab 58 MYDICAR ® 58 CCR9 antagonist 58 adult chronic ITP 58 tenofovir disoproxil fumarate Viread 57 DUROS 57 VentiRx Pharmaceuticals 57 ZOLINZA 57 Oral Spray 57 Tarvacin TM 57 CIMZIA ™ 57 metastatic malignant 57 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 57 bardoxolone 57 gemcitabine Gemzar ® 57 novel oral anticoagulant 57 Alferon N 57 Initiates Phase II 57 hyaluronidase enzyme 57 isoform selective 57 Carfilzomib 57 xenograft models 57 CD3 monoclonal antibody 57 drug eluting coronary stent 57 Velcade bortezomib 57 AP# [003] 57 Fx #A 57 Anticalin R 57 paclitaxel Taxol 57 corticosteroid dexamethasone 57 apaziquone 57 Litx 57 PRT# 57 MOZOBIL 57 Randomized Phase 57 bevacizumab Avastin R 57 Pivotal Phase III 57 fluoropyrimidine 57 CIMZIA TM 57 ongoing Phase 1b 57 Solazed 57 evaluating satraplatin 57 Civacir 57 SCH # 57 Ridaforolimus 57 sorafenib Nexavar 57 Alkeran 57 selective antagonist 57 MGCD# [001] 57 Plicera 57 Endologix Powerlink System 57 GAMMAGARD 57 mitomycin 57 tanespimycin 57 TBC# 57 DU #b 57 KNS # 57 Epratuzumab 57 IRESSA 57 Exelixis compounds 57 Capesaris 57 GW# [003] 57 hematological malignancies 57 Talabostat 57 PegIFN 57 Curaxin CBLC# 57 Frova ® 57 bortezomib Velcade 57 biologic DMARD 57 BiTE antibody 57 Cetrorelix 57 catheter occlusion 57 Quinamed 57 Sufentanil 57 Ocrelizumab 57 DURECT proprietary 57 TLK# 57 IV Busulfex 57 mu opioid receptor antagonist 57 OvaRex R 57 cediranib 57 belinostat 57 SYN# 57 rusalatide acetate 57 phase IIb trial 57 advanced hepatocellular carcinoma 57 Otelixizumab 57 TMC# [002] 57 Meets Primary Endpoint 57 GLP1 INT TM 57 investigational oral 57 PEG Interferon lambda 57 occlusion PAO 57 TO AVOID PREGNANCY WHILE 57 FOLFOX6 57 VAPRISOL 57 Panzem ® 57 cannabinor 57 Pazopanib 57 vaccines oncolytic virus 57 BRIM2 57 thymalfasin 57 patented Bioral 57 Exelixis XL# 57 Vascular Disrupting Agent 57 Initiate Phase 57 Genasense ® 57 SNT MC# 57 Pemetrexed 57 Preclinical studies suggest 57 Vinorelbine 57 OMP #M# 57 selective adenosine 57 Pivotal Phase 57 kinase inhibitor 57 enzyme rHuPH# 57 SCCHN 57 AMEVIVE 57 VBLOC R 57 initiate Phase 1b 57 PEG interferon 57 dirucotide 57 EGFR TKIs 57 Pennsaid R 57 LymphoStat B belimumab 57 FOLOTYN 57 ATL# [002] 57 cetuximab Erbitux ® 57 Entereg R 57 omega interferon 57 Cloretazine 57 Alemtuzumab 57 brand ciclesonide HFA 57 Fibrillex TM 57 HspE7 57 NGX# 57 Tanespimycin 57 acting neuraminidase inhibitor 57 custirsen 57 anti EGFR antibody 57 Ophena TM 57 ZD# [001] 57 thymidylate synthase TS 56 Phase 1a clinical 56 DAVANAT 56 perifosine 56 PANVAC VF 56 obatoclax 56 MET RET 56 ORENCIA ® 56 Aptivus ® 56 Romidepsin 56 metastatic hormone refractory 56 aflibercept 56 Elagolix 56 zanolimumab 56 Vivecon 56 Cutaneous T 56 HER2 positive metastatic breast 56 Vidaza azacitidine 56 terlipressin 56 myelofibrosis polycythemia vera 56 PI3K inhibitor 56 Phase Ib clinical 56 dose cohort 56 TG# [001] 56 assessing T DM1 56 TASQ 56 metastatic renal cell carcinoma 56 Allovectin 7 ® 56 Onyx Pharmaceuticals Announces 56 StemEx 56 lymphoid malignancies 56 dimesylate 56 Phase IIb trials 56 SARMs 56 Uricase PEG 56 CLORETAZINE TM VNP#M 56 TRX# 56 TKM ApoB 56 EndoBarrier ™ 56 PXD# 56 BEXXAR 56 Hsp# inhibitor 56 QuadraSphere 56 seliciclib 56 ARIKACE ™ 56 RITUXAN 56 Achieves Primary Endpoint 56 adecatumumab MT# 56 Interferon beta 1a 56 postoperative ileus POI 56 ara C 56 gastrointestinal stromal tumors 56 Canvaxin TM 56 Hepatocellular Carcinoma HCC 56 PSN# [002] 56 ularitide 56 Uvidem 56 Laquinimod 56 amrubicin 56 inhibitor PPI 56 Eraxis 56 Resten NG 56 Ganciclovir 56 Sanvar R 56 dextromethorphan quinidine 56 Zolinza 56 POTELLIGENT ® 56 EP #R 56 AZX# 56 ISIS # 56 BrachySil ™ 56 Xerecept 56 CRMD# 56 SUMAVEL 56 Kahalalide F 56 ISF# 56 TH# [003] 56 Gastrointestinal Stromal Tumors 56 Adenosine Therapeutics 56 Telintra 56 NVA# 56 Cellgate 56 Zerenex 56 XMT 56 ® natalizumab 56 OSMOPREP 56 Vicriviroc 56 PRN FDA Approves 56 L BLP# 56 hypoxia activated prodrug 56 radiolabeled monoclonal antibody 56 ALK inhibitor 56 Mg Usa 56 Apoptone 56 elacytarabine 56 BrachySil 56 EnteroMedics proprietary neuroblocking technology 56 Phase III Pivotal 56 Intraject 56 refractory NSCLC 56 ELACYT 56 Silodosin 56 Bayer HealthCare Onyx Pharmaceuticals 56 HCV protease 56 Ketotransdel 56 Æterna Zentaris 56 Phenoptin 56 PRTX 56 fludarabine phosphate 56 LHRH receptor positive 56 TLR8 agonist 56 Serostim ® 56 #ME# 56 granisetron formulated 56 Tesmilifene 56 Clolar ® 56 GSK # 56 NOD SCID mice 56 MAP# 56 IND enabling 56 castration resistant prostate cancer 56 prostone 56 BiTE 56 ErbB2 positive 56 RP# [002] 56 ixabepilone 56 aldehyde dehydrogenase ALDH2 deficiency 56 novel nucleoside analog 56 potent CYP#A# inhibitors 56 Symadex 56 Vilazodone 56 Acute Heart Failure 56 BIO Pte Ltd 56 Galantamine 56 Aplidin 56 Enzyme Replacement Therapy 56 randomized controlled Phase 56 zileuton 56 Doxorubicin 56 BHT DNA 56 carcinoid syndrome 55 imetelstat 55 Gleevec imatinib mesylate 55 posaconazole 55 refractory prostate cancer 55 rNAPc2 55 taxane chemotherapy 55 Electronic Brachytherapy System 55 pralatrexate 55 fosbretabulin 55 oral nucleoside analogue 55 Fodosine 55 INCB# [002] 55 Luveniq 55 cancer neuroendocrine tumor 55 metastatic HRPC 55 MKC# 55 teriflunomide 55 Dyloject TM 55 serum biomarker 55 LymphoStat B 55 PEGASYS ® 55 Pharmion Corporation 55 ONCONASE 55 TRISENOX 55 MET amplification 55 CAMPATH 55 K RAS 55 molecular imaging radiopharmaceutical 55 LentiVector 55 Files Investigational 55 Alvesco R 55 Amikacin Inhale 55 Saizen R 55 TOCOSOL 55 DB# [003] 55 XL# [003] 55 Dacogen injection 55 Phase IIb Clinical Trial 55 Hodgkin lymphoma HL 55 GetGoal Phase III 55 Octreotide 55 IMP# 55 ARIKACE 55 LBH# 55 tumor xenograft models 55 CorVue ™ 55 unique alkylating agent 55 PARP inhibitors 55 PEGPH# 55 Proxinium TM 55 humanised antibody 55 transthyretin TTR mediated amyloidosis 55 demethylating agent 55 CoFactor 55 CG# [001] 55 oral chemotherapeutic agent 55 AVASTIN 55 Enzastaurin 55 IMGN# 55 CR# vcMMAE 55 Exemestane 55 Zemiva ™ 55 Herceptin trastuzumab 55 urethral bulking agent 55 aromatase inhibitor AI 55 Hsp# inhibitors 55 CD# antibody [001] 55 Abbokinase 55 regorafenib 55 Enkephalin 55 Gefitinib 55 BROVANA 55 trastuzumab DM1 T DM1 55 HCl Injection 55 otelixizumab 55 danoprevir 55 Hsp# inhibition 55 lumiliximab 55 PROMACTA ® 55 TACI Ig 55 Panzem 55 Ambrisentan 55 NY ESO 55 mRCC 55 MyVax R 55 Nexavar sorafenib tablets 55 Nilotinib 55 Genentech Rituxan 55 talactoferrin 55 Pharmacokinetics PK 55 either acutely decompensated 55 GSK# [001] 55 investigational compound 55 Inhaled AAT 55 SUTENT ® 55 inhalation aerosol 55 Aerosurf 55 dopamine partial agonist 55 metabolic inhibitor 55 GeneICE 55 GRNVAC1 55 Virulizin R 55 OHR/AVR# 55 Pimavanserin 55 class mGluR5 inhibitor 55 lapatinib Tykerb 55 geldanamycin 55 BR.# 55 muraglitazar 55 Dural Regeneration Matrix 55 tamibarotene 55 AERx ® 55 MGCD# [002] 55 platelet aggregation inhibitor 55 essential thrombocythemia ET 55 gastrointestinal stromal tumor GIST 55 ALVESCO R 55 fluticasone furoate 55 E1 INT TM 55 registrational trial 55 ridaforolimus 55 enzastaurin 55 INGN 55 vincristine doxorubicin 55 ALN VSP 55 Preclinical Models 55 Sumatriptan Succinate 55 Revimmune 55 miRview mets 55 dirucotide MBP# 55 HaptoGuard 55 multicenter Phase 55 gallium containing 55 paclitaxel poliglumex 55 Vitaxin 55 lesinurad 55 Imprime PGG 55 HepaSphere 55 pharmacodynamic PD 55 RG# [001] 55 MAXY alpha 55 liver resection surgeries 55 Tyrima 55 relapsing remitting MS RRMS 55 Pancreate 55 metastatic bladder 55 Adenoscan 55 HDACi 55 Methylnaltrexone 55 Arranon 55 sorafenib Nexavar ® 55 MDV# 55 gemtuzumab ozogamicin 55 Celgene Thalomid 55 prostate cancer AIPC 55 refractory gout 55 eculizumab 55 Intravesical 55 DDP# 55 BRAF inhibitor 55 Imatinib mesylate 55 Targretin 55 PRIALT 54 Nasulin TM 54 Phase 1b 54 ASONEP 54 sd rxRNA 54 CRLX# 54 recurrent glioblastoma 54 LUX Lung 54 lomitapide 54 plasmid encoding 54 Evoltra 54 low dose cytarabine 54 CRx 54 trial evaluating PRX# 54 REVEAL Registry 54 temsirolimus 54 adenosine A2A 54 Phase 2b clinical trials 54 Isis Pharma 54 Targretin capsules 54 JAK3 54 ALVESCO ® 54 DEB# 54 IFN α 54 refractory AML 54 fostamatinib 54 Commences Phase 54 hematological cancers 54 FavId 54 GLPG# 54 combinability 54 lorvotuzumab mertansine 54 Nipent R 54 nasal spray formulation 54 HuMax HepC 54 Ultratrace 54 K ras mutations 54 recurrent glioblastoma multiforme 54 orthotopic model 54 Hemopurifier ® 54 Delcath PHP System 54 tezampanel 54 castrate resistant 54 tafamidis 54 Hedgehog Pathway Inhibitor 54 Propofol IDD D 54 Xelox 54 Multiple Myeloma MM 54 axitinib 54 brivaracetam 54 mTOR inhibitors 54 teplizumab 54 bortezomib Velcade ® 54 recombinant adeno associated 54 cutaneous T cell 54 BLP# Liposome Vaccine 54 HyperAcute 54 Astellas Deutschland GmbH 54 Receptor Antagonists 54 NKTR 54 personalized immunotherapy 54 Cethrin 54 adecatumumab 54 samalizumab 54 Epirubicin 54 PG# [004] 54 Initiates Clinical Trials 54 commercialize deforolimus 54 EnVivo 54 Versartis 54 ProLindac 54 HuMax CD# 54 alagebrium 54 multiple myeloma MM 54 #D#C# 54 Receptor Antagonist 54 AZD# 54 Relapsed Refractory 54 lidocaine hydrochloride monohydrate powder 54 Radezolid 54 registrational 54 hematologic disorders 54 methylnaltrexone 54 darapladib 54 romidepsin 54 chronic idiopathic thrombocytopenic purpura 54 Genz # 54 PREOS 54 efalizumab 54 systemic immunosuppressive drugs 54 Deadlinepix 54 UPLYSO 54 relapsing remitting multiple sclerosis 54 myelodysplastic syndrome MDS 54 hematological malignancy 54 Delafloxacin 54 pomalidomide 54 Mepact 54 BRIM3 54 phase Ib 54 Cimzia ® certolizumab pegol 54 Myelodysplastic Syndrome MDS 54 Vidofludimus 54 vemurafenib 54 subcutaneous implant 54 Gemcitabine 54 subcutaneous Herceptin 54 Olaparib 54 OncoVEX 54 refractory metastatic colorectal cancer 54 epilepsy neuropathic pain 54 Azedra TM 54 albinterferon alfa 2b 54 relapsed MM 54 Cloretazine R 54 VBLOC TM 54 colorectal carcinoma 54 metformin XR 54 BEMA TM Fentanyl 54 Tocosol Paclitaxel 54 neratinib 54 Pennsaid ® 54 KRN# 54 DURIN TM 54 EGFR inhibitors 54 diabetes irritable bowel 54 Triapine 54 catheter occlusion CO 54 Cimzia TM 54 rituximab Rituxan 54 Phase 2b Trial 54 oral transmucosal 54 Initiate Clinical Trial 54 Syncria 54 EGF receptor 54 pradefovir 54 tesetaxel 54 endoluminal stent graft 54 fallopian tube carcinoma 54 unresectable locally advanced 54 ON #.Na 54 androgen independent 54 Exherin TM 54 inhaled treprostinil